Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064521 | 0.94 | ALDH1A1 (0.44) | TP53KDM4EALDH1A1HSD17B10HDAC1 | |
| SCHEMBL12933479 | 0.90 | TP53 (0.46) | TP53KDM4EALDH1A1HSD17B10THRB | |
| SCHEMBL12933480 | 0.87 | TP53 (0.46) | TP53KDM4EALDH1A1HSD17B10THRB | |
| SCHEMBL12933433 | 0.87 | TP53 (0.52) | TP53THRB | |
| SCHEMBL1062757 | 0.86 | SMO (0.49) | TP53KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL12963074 | 0.84 | DRD4 (0.43) | ALDH1A1HDAC1HDAC6LMNA | |
| SCHEMBL1062151 | 0.83 | SMO (0.46) | TP53KDM4EALDH1A1HSD17B10THRB | |
| SCHEMBL1059982 | 0.82 | SMO (0.47) | — | |
| SCHEMBL1060796 | 0.81 | POLB (0.42) | TP53KDM4EALDH1A1HSD17B10THRB | |
| SCHEMBL1062906 | 0.81 | DRD4 (0.43) | TP53KDM4EALDH1A1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399449-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | TP53 3556/4885KDM4E 528/4885ALDH1A1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.